COVID-19 updates
|
COVID-19 Update
The FDA has updated to the EUA for the COVID-19 monoclonal antibody combination of tixagevimab plus cilgavimab (Evusheld) to indicate that Omicron subvariant BA.4.6 is not susceptible to the antibody combination. Comments are closed.
|
Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker
Archives
January 2023
Categories |
RSS Feed